Genetic targeting of the kinase activity of the Met receptor in cancer cells
- 3 July 2007
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 104 (27), 11412-11417
- https://doi.org/10.1073/pnas.0703205104
Abstract
The development of kinase inhibitors is revolutionizing cancer treatment. Assessing the oncogenic potential of individual kinase activities and ensuring that a drug of interest acts by direct inhibition of its putative target kinase are clear priorities. We developed a genetic strategy to selectively inactivate the catalytic activity of kinases. This approach generates isogenic cells in which a given kinase gene is expressed but is devoid of enzymatic activity. As a model to test this approach, we chose the MET receptor, which is involved in multiple cancers and is the focus of several therapeutic efforts. The exon encoding the ATP-binding site of MET was deleted from the genome of colorectal, bladder, and endometrial cancer cells. The derivative isogenic cells expressed a kinase-inactive Met (MET-KD) and were completely unresponsive to its ligand hepatocyte growth factor (HGF), indicating the exclusivity of this ligand-receptor axis. The in vivo tumorigenic potential of MET-KD cells was reduced but could be partially restored by HGF, suggesting that concomitant targeting of the receptor and its ligand should be therapeutically exploited. A reportedly selective Met-kinase inhibitor (SU-11274) markedly affected the growth of MET-KD cancer cells, indicating this compound exerts its effects not only through the intended target. The genetic strategy presented here is not limited to kinase genes but could be broadly applicable to any drug/protein combination in which the target enzymatic domain is known.Keywords
This publication has 23 references indexed in Scilit:
- Comparing antibody and small-molecule therapies for cancerNature Reviews Cancer, 2006
- The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsOncogene, 2004
- A census of human cancer genesNature Reviews Cancer, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- The Semaphorin 4D receptor controls invasive growth by coupling with MetNature, 2002
- Scatter-factor and semaphorin receptors: cell signalling for invasive growthNature Reviews Cancer, 2002
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasOncogene, 2000
- Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasisOncogene, 1999
- The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro.Molecular Biology of the Cell, 1996